Contributions
Abstract: EP1801
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Background: Use of disease modifying therapy in real-world MS populations is heterogeneous, reflecting physician and patient preferences, and health system considerations. For example, in the single-centre EPIC cohort, 40.4% of patients were not on a disease modifying therapy (DMT) at baseline, while in MSBase, an international multi-centre cohort, 21.9% of patients were not on a DMT. Variability in DMT use across practices, regions, and countries has received little systematic study to date. Important confounders or biases (i.e. channelling bias) may underlie this variability and should be taken into account conducting observational patient outcomes research.
Objectives: To describe treatment patterns and associated demographic and clinical characteristics among patients participating in the MS PATHS network.
Methods: During routine clinic visits patients answered standardized questionnaires, including use of DMTs, using the MS Performance Test, an iPad-based device. Current DMT use, patient demographics, and MS characteristics were characterized and analyzed using descriptive statistics, ANOVA, and Chi-square tests of independence
Results: The sample comprised 1353 patients. Mean (SD) age was 48.9 (12.0), disease duration 12.2 years (9.4), age of diagnosis was 36.4 (10.9) and PDDS was 2.4 (2.2). 19.2% of patients reported no current DMT use. This group was older and more disabled compared to the 80.2% of patients who reported current DMT use. The five most common DMTs (in descending order) were dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab and interferons. In comparison, the five most common DMTs based on US market estimates were glatiramer acetate, interferons, dimethyl fumarate, fingolimod and natalizumab. Within MS PATHS the longest disease duration (mean=17.5 years, sd=10.5) and the lowest PDDS scores (1.5, 2.0) were among interferon patients; the youngest age (42.0, 10.2) was observed among natalizumab patients.
Conclusions: DMT use patterns differed in the MS PATHS network sites compared with external benchmarks. Overall DMT use was similar to MSBase, but higher than reported from EPIC. Glatiramer acetate and interferon use was less frequent in MS PATHS sites compared to US market estimates. MS PATHS interferon users had longer disease duration and lower disability scores. Factors relating to treatment pattern heterogeneity across the international network will be presented.
Disclosure: Project funded by Biogen, Inc.
Bernd C. Kieseier, James R. Williams, Carl de Moor, Glenn A. Phillips and Richard Rudick are employees of, and stockholders in, Biogen.
Megan Hyland is employed by the University of Rochester which receives funding from Biogen, Chugai and Novartis.
Abstract: EP1801
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Background: Use of disease modifying therapy in real-world MS populations is heterogeneous, reflecting physician and patient preferences, and health system considerations. For example, in the single-centre EPIC cohort, 40.4% of patients were not on a disease modifying therapy (DMT) at baseline, while in MSBase, an international multi-centre cohort, 21.9% of patients were not on a DMT. Variability in DMT use across practices, regions, and countries has received little systematic study to date. Important confounders or biases (i.e. channelling bias) may underlie this variability and should be taken into account conducting observational patient outcomes research.
Objectives: To describe treatment patterns and associated demographic and clinical characteristics among patients participating in the MS PATHS network.
Methods: During routine clinic visits patients answered standardized questionnaires, including use of DMTs, using the MS Performance Test, an iPad-based device. Current DMT use, patient demographics, and MS characteristics were characterized and analyzed using descriptive statistics, ANOVA, and Chi-square tests of independence
Results: The sample comprised 1353 patients. Mean (SD) age was 48.9 (12.0), disease duration 12.2 years (9.4), age of diagnosis was 36.4 (10.9) and PDDS was 2.4 (2.2). 19.2% of patients reported no current DMT use. This group was older and more disabled compared to the 80.2% of patients who reported current DMT use. The five most common DMTs (in descending order) were dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab and interferons. In comparison, the five most common DMTs based on US market estimates were glatiramer acetate, interferons, dimethyl fumarate, fingolimod and natalizumab. Within MS PATHS the longest disease duration (mean=17.5 years, sd=10.5) and the lowest PDDS scores (1.5, 2.0) were among interferon patients; the youngest age (42.0, 10.2) was observed among natalizumab patients.
Conclusions: DMT use patterns differed in the MS PATHS network sites compared with external benchmarks. Overall DMT use was similar to MSBase, but higher than reported from EPIC. Glatiramer acetate and interferon use was less frequent in MS PATHS sites compared to US market estimates. MS PATHS interferon users had longer disease duration and lower disability scores. Factors relating to treatment pattern heterogeneity across the international network will be presented.
Disclosure: Project funded by Biogen, Inc.
Bernd C. Kieseier, James R. Williams, Carl de Moor, Glenn A. Phillips and Richard Rudick are employees of, and stockholders in, Biogen.
Megan Hyland is employed by the University of Rochester which receives funding from Biogen, Chugai and Novartis.